Opinion
Video
Translating Data With Oral SERDs to Practice: EMBER-3, SERENA-2, and Ongoing Trials
Author(s):
Dr. Gandhi and Dr. Clifton discuss incorporating imlunestrant plus abemaciclib into treatment sequencing for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (BC), considering factors such as ESR1 mutation status, prior CDK4/6 inhibitor (CDK4/6i) use, and visceral metastases, while also highlighting key trials of selective estrogen receptor degraders (SERDs), including SERENA-2 and OPERA-01.
Video Player is loading.
Video content above is prompted by the following:
- Based on the data seen in the EMBER-3 trial, how do you anticipate incorporating imlunestrant plus abemaciclib into your treatment sequencing for patients with HR+/HER2– metastatic BC? In which patients and in which line of therapy would you consider using this combination?
- Based on subgroup data, how might you consider these factors in your clinical decision-making?
- ESR1 mutation vs wild type
- Prior CDK4/6i
- Duration of prior CDK4/6i
- Presence of visceral metastases
- Based on subgroup data, how might you consider these factors in your clinical decision-making?
- Please highlight other trials of note investigating SERDs in HR+/HER2– BC:
- SERENA-2: camizestrant vs fulvestrant
- OPERA-01: palazestrant vs standard-of-care endocrine therapy
- Any others (eg, EMBER-4, SERENA-4,ELEVATE, etc)
Related Videos
Key Updates in the Treatment of ES-SCLC
Expert Insights on Recent Advancements in LS-SCLC
Reflections and Future Directions in R/R ALL
Outpatient CAR T Therapy and Expanding Access
FLAURA and FLAURA2: Key Efficacy and Safety Data
Health Care Resource Utilization and Transition of Care
The Importance of Early Biomarker Testing in Managing Advanced BTC
Guiding Patients Through Advanced BTC Prognosis and Expectations
Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases
Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases
Related Content
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
